Immunoassays for drug monitoring are key analytical tools in various clinical and non-clinical settings. To use them with the least harmful impact on patient care, there is a need to understand what factors could contribute to unexpected results to accurately identify the course of clinical action. Inaccurate characterization of an immunoassay performance creates unnecessary confusion with unwanted impact and thus undermines assay utility.
A new white paper explores the complexities of cross-reactivity in immunoassays used for drug monitoring:
- Misinterpretation of immunoassay results can negatively impact patient care.
- Choosing the correct assay and understanding its limitations is crucial for clinical decision-making.